Movement disorders in children: recent advances in management.
In recent years there has been a growing interest towards pediatric movement disorders (PMD). The data derived from the synthesis of clinical observation, neuroimaging, biochemical and, molecular genetics studies have allowed for the identification of a significant number of pediatric diseases featuring movement disorders. The purpose of this review is to outline an approach to the advances in management of dystonia, neurotransmitter disorders, tics, and paroxysmal dyskinetic syndromes starting in children younger than 18 yr of age.
Fernández-Alvarez
Emilio
E
Neuropediatric Department, Hospital Universitario Sant Joan de Déu, Avda Sant Joan de Déu 2, Barcelona, Spain. efernandez@hsjdbcn.org
D017677:Age Distribution; D017668:Age of Onset; D001418:Baclofen / Q000627:therapeutic use; D001569:Benzodiazepines / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D018680:Cholinergic Antagonists / Q000627:therapeutic use*; D015259:Dopamine Agents / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D020820:Dyskinesias / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology; D042241:Early Diagnosis; D004576:Electromyography; D005260:Female; D006801:Humans; D015994:Incidence; D007223:Infant; D007980:Levodopa / Q000627:therapeutic use; D008297:Male; D009069:Movement Disorders / Q000175:diagnosis* / Q000188:drug therapy* / Q000453:epidemiology; D010808:Physical Examination; D011379:Prognosis; D018570:Risk Assessment; D012720:Severity of Illness Index; D017678:Sex Distribution; D013030:Spain; D016896:Treatment Outcome
D018680:Cholinergic Antagonists; D015259:Dopamine Agents; D001569:Benzodiazepines; D007980:Levodopa; D001418:Baclofen